The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Overview of the Phase III ENHANCE trial schema
David Sallman
• 11 Dec 2021
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, briefly highlights the patient cohort, trial schema, and primary endpoints of the Phase III ENHANCE trial (NCT04313881), which is investigating the development of a new standard of care for patients with high-risk myelodysplastic syndromes (HR-MDS). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
